Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells

Journal of Immunology

Volumn 177, Issue 12, 2006, Pages 8381-8392

  Konforte, Danijela ^a   Paige, Christopher J ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HLA DR ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 21; JANUS KINASE; JANUS KINASE INHIBITOR; MYC PROTEIN; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOREGULATION; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 33845438994     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.12.8381     Document Type: Article

References (60)

1. c-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202: 67-83.
2. Noguchi, M., Y. Nakamura, S. M. Russell, S. F. Ziegler, M. Tsang, X. Cao, and W. J. Leonard. 1993. Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 262: 1877-1880.
3. Parrish-Novak, J., S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63.
4. Parrish-Novak, J., D. C. Foster, R. D. Holly, and C. H. Clegg. 2002. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukocyte Biol. 72: 856-863.
5. Chtanova, T., S. G. Tangye, R. Newton, N. Frank, M. R. Hodge, M. S. Rolph, and C. R. Mackay. 2004. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173: 68-78.
6. Mehta, D. S., A. L. Wurster, A. S. Weinmann, and M. J. Grusby. 2005. NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression. Proc. Natl. Acad. Sci. USA 102: 2016-2021.
7. + T cell expansion and function. J. Exp. Med. 201: 139-148.
8. Ma, H. L., M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos. 2003. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. 171: 608-615.
9. + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol. 33: 3439-3447.
10. Brady, J., Y. Hayakawa, M. J. Smyth, and S. L. Nutt. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172: 2048-2058.
11. Wang, G., M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, G. Kim, W. J, Leonard, and P. Hwu. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63: 9016-9022.
12. Di Carlo, E., A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini. 2004. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172: 1540-1547.
13. Kishida, T., H. Asada, Y. Itokawa, F. D. Cui, M. Shin-Ya, S. Gojo, K. Yasutomi, Y. Ueda, H. Yamagishi, J. Imanishi, and O. Mazda. 2003. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 8: 552-558.
14. Jin, H., R. Carrio, A. Yu, and T. R. Malek. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173: 657-665.
15. Ozaki, K., R. Spolski, R. Ettinger, H. P. Kim, G. Wang, C. F. Qi, P. Hwu, D. J. Shaffer, S. Akilesh, D. C. Roopenian, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173: 5361-5371.
16. Ettinger, R., G. P. Sims, A. M. Fairhurst, R. Robbins, Y. S. da Silva, R. Spolski, W. J. Leonard, and P. E. Lipsky. 2005. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175: 7867-7879.
17. Brenne, A. T., T. Baade Ro, A. Waage, A. Sundan, M. Borset, and H. Hjorth-Hansen. 2002. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99: 3756-3762.
18. de Totero, D., R. Meazza, S. Zupo, G. Cutrona, S. Maus, M. Colombo, E. Balleari, I. Pierri, M. Fabbi, M. Capaia, et al. 2006. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates pro-apoptotic signals in chronic lymphocytic leukemia B cells. Blood 107: 3708-3715.
19. Johnson, K., M. Shapiro-Shelef, C. Tunyaplin, and K. Calame. 2005. Regulatory events in early and late B-cell differentiation. Mol. Immunol. 42: 749-761.
20. Shapiro-Shelef, M., and K. Calame. 2005. Regulation of plasma-cell development. Nat. Rev. Immunol. 5: 230-242.
21. Young, L. S., and A. B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4: 757-768.
22. Leonard, W. J., and R. Spolski. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5: 688-698.
23. Zimber-Strobl, U., and L. J. Strobl. 2001. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin. Cancer Biol. 11: 423-434.
24. Uchida, J., T. Yasui, Y. Takaoka-Shichijo, M. Muraoka, W. Kulwichit, N. Raab-Traub, and H. Kikutani. 1999. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286: 300-303.
25. Adhikary, S., and M. Eilers. 2005. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6: 635-645.
26. Melchers, F. 1997. B-lymphocyte-lineage cells from early precursors to Ig-secreting plasma cells: targets of regulation by the myc/mad/max families of genes? Curr. Top. Microbiol. Immunol. 224: 19-30.
27. Yang, W., J. Shen, M. Wu, M. Arsura, M. FitzGerald, Z. Suldan, D. W. Kirn, C. S. Hofmann, S. Pianetti, R. Romieu-Mourez, et al. 2001. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20: 1688-1702.
28. Shaffer, A. L., K. I. Lin, T. C. Kuo, X. Yu, E. M. Hurt, A. Rosenwald, J. M. Giltnane, L. Yang, H. Zhao, K. Calame, and L. M. Staudt. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17: 51-62.
29. Shaffer, A. L., X. Yu, Y. He, J. Boldrick, E. P. Chan, and L. M. Staudt. 2000. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13: 199-212.
30. Thompson, J. E., R. M, Cubbon, R. T. Cummings, L. S. Wicker, R. Frankshun, B. R. Cunningham, P. M. Cameron, P. T. Meinke, N. Liverton, Y. Weng, and J. A. DeMartino. 2002. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12: 1219-1223.
31. Vernino, L., L. M. McAnally, J. Ramberg, and P. E. Lipsky. 1992. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. J. Immunol. 148: 404-410.
32. Merville, P., J. Dechanet, G. Grouard, I. Durand, and J. Banchereau. 1995. T cell-induced B cell blasts differentiate into plasma cells when cultured on bone marrow stroma with IL-3 and IL-10. Int. Immunol. 7: 635-643.
33. Arpin, C., J. Dechanet, C. Van Kooten, P. Merville, G. Grouard, F. Briere, J. Banchereau, and Y. J. Liu. 1995. Generation of memory B cells and plasma cells in vitro. Science 268: 720-722.
34. Tangye, S. G., D. T. Avery, and P. D. Hodgkin. 2003. A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J. Immunol. 170: 261-269.
35. Avery, D. T., J. I. Ellyard, F. Mackay, L. M. Corcoran, P. D. Hodgkin, and S. G. Tangye. 2005. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J. Immunol. 174: 4034-4042.
36. MacLennan, I. C., K. M. Toellner, A. F. Cunningham, K. Serre, D. M. Sze, E. Zuniga, M. C. Cook, and C. G. Vinuesa. 2003. Extrafollicular antibody responses. Immunol. Rev. 194: 8-18.
37. Thorley-Lawson, D. A., and A. Gross. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350: 1328-1337.
38. Karagiannis, S. N., J. K. Warrack, K. H. Jennings, P. R. Murdock, G. Christie, K. Moulder, B. J. Sutton, and H. J. Gould. 2001. Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. Immunology 103: 319-331.
39. Bonnefoy, J. Y., S. Lecoanet-Henchoz, J. F. Gauchat, P. Graber, J. P. Aubry, P. Jeannin, and C. Plater-Zyberk. 1997. Structure and functions of CD23. Int. Rev. Immunol. 16: 113-128.
40. Visan, I., M. Goller, I. Berberich, C. Kneitz, and H. P. Tony. 2003. Pax-5 is a key regulator of the B cell-restricted expression of the CD23a isoform. Eur. J. Immunol. 33: 1163-1173.
41. Weber-Nordt, R. M., R. Mertelsmann, and J. Finke. 1998. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leak. Lymphoma 28: 459-467.
42. Imada, K., and W. J. Leonard. 2000. The Jak-STAT pathway. Mol. Immunol. 37: 1-11.
43. Ihle, J. N. 2001. The Stat family in cytokine signaling. Curr. Opin. Cell Biol. 13: 211-217.
44. Lin, K. I., Y. Lin, and K. Calame. 2000. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol. Cell Biol. 20: 8684-8695.
45. Larsson, L. G., M. Schena, M. Carlsson, J. Sallstrom, and K. Nilsson. 1991. Expression of the c-myc protein is down-regulated at the terminal stages during in vitro differentiation of B-type chronic lymphocytic leukemia cells. Blood 77: 1025-1032.
46. Lin, Y., K. Wong, and K. Calame. 1997. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 276: 596-599.
47. Nutt, S. L., J. Brady, Y. Hayakawa, and M. J. Smyth. 2004. Interleukin 21: a key player in lymphocyte maturation. Crit. Rev. Immunol. 24: 239-250.
48. Mehta, D. S., A. L. Wurster, and M. J. Grusby. 2004. Biology of IL-21 and the IL-21 receptor. Immunol. Rev. 202: 84-95.
49. Williamson, P., I. Merida, and G. Gaulton. 1993. Protein and lipid kinase activation cascades in interleukin-2 receptor signalling. Semin. Immunol. 5: 337-344.
50. Benczik, M., and S. L. Gaffen. 2004. The interleukin (lL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest. 33: 109-142.
51. Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan, and W. E. Paul. 1999. The IL-4 receptor signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17: 701-738.
52. Milne, C. D., and C. J. Paige. 2006. IL-7: a key regulator of B lymphopoiesis. Semin. Immunol. 18: 20-30.
53. Stephanou, A., and D. S. Latchman. 2005. Opposing actions of STAT-1 and STAT-3. Growth Factors 23: 177-182.
54. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Daraell, Jr. 1999. Stat3 as an oncogene. Cell 98: 295-303.
55. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
56. Lee, C. K., E. Smith, R. Gimeno, R. Gertner, and D. E. Levy. 2000. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-γ. J. Immunol. 164: 1286-1292.
57. Kumar, A., M. Commane, T. W. Flickinger, C. M. Horvath, and G. R. Stark. 1997. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278: 1630-1632.
58. Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19: 2474-2488.
59. Garcia, R., T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C. E. Cox, R. Falcone, R. Fairclough, S. Parsons, et al. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513.
60. Grandis, J. R., S. D. Drenning, A. Chakraborty, M. Y. Zhou, Q. Zeng, A. S. Pitt, and D. J. Tweardy. 1998. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J. Clin. Invest. 102: 1385-1392.